Zerion Pharma
Zerion Pharma
Zerion Pharma is a Danish pharmaceutical company transforming the pharmaceutical landscape for the formulation of poorly soluble drugs that are currently not reaching their therapeutic potential. Through the use of our proprietary formulation platform, Dispersome®, we aim to develop new treatment options for patients across all small-molecule therapy areas. We are focused on improving the formulation of poorly soluble oral drugs, both for innovator drugs and existing drug products.
Dispersome® Technology
Dispersome® is Zerion Pharma’s innovative solubility enhancement platform designed to address the challenges of poorly soluble small-molecule drugs.
Key Features
- High Drug Loading: Enables drug loadings above 50% w/w while maintaining stability.
- Improved Bioavailability: Increases solubility and dissolution rates, leading to enhanced therapeutic outcomes.
- Manufacturing Compatibility: Compatible with standard solid oral dosage form manufacturing processes, including spray drying.
- Environmental Sustainability: Uses BLG, a highly pure whey protein which is a safe, natural, and environmentally friendly by-product from cheese production, reducing reliance on fossil-based polymers.
- Patent protection extending beyond 2040.
Dispersome® explained in 1 minute:
The Dispersome® technology is based on the use of beta-lactoglobulin (BLG) to create Dispersomes® – a unique amorphous composition of small molecule drugs and proteins. The preparation of a Dispersome® formulation is straightforward and easy to integrate in existing industry standard manufacturing processes.
Improved dissolution profile
Dispersome® formulation achieves a superior dissolution rate and better solubility compared to other solid dispersions when addressing a poorly soluble drug, ZN-X.
Positive data from the first human study
The partnership with Insud Pharma has yielded positive results from the first human clinical study of a Dispersome® formulation of the drug Ivacaftor, a pharmaceutical used to treat cystic fibrosis.The study, involving 18 healthy volunteers, showed enhanced bioavailability. One of the Ivacaftor Dispersome® formulations showed improved bioavailability compared to the reference product, while the pharmacokinetic parameters for the second formulation were equivalent to Kalydeco®. Both Ivacaftor Dispersome® formulations carried high content (drug load) of Ivacaftor and were designed to increase the solubility of this poorly soluble compound.
Zerion operates worldwide, offering solutions to pharmaceutical companies seeking to overcome solubility challenges in drug development. For more information on Zerion Pharma’s Dispersome® technology and partnership opportunities, please visit us.
Scientific Validation
At Zerion Pharma, science is at the core of everything we do. Our proprietary Dispersome® technology is grounded in cutting-edge research and validated through a growing portfolio of peer-reviewed scientific publications. This strong scientific foundation reinforces the performance, safety, and innovation behind our solutions.
A recent highlight is our 2024 publication in the European Journal of Pharmaceutics and Biopharmaceutics, showcasing the latest advancements in protein-based amorphous solid dispersions:
Read the publication here: A graphical review on the state-of-the-art. Eur. J. Pharm. Biopharm. 2024;202:114396.
Discover more of our scientific work on our website:
Commitment to Innovation & Sustainability
Zerion Pharma is committed to delivering smarter, simpler, and greener drug formulations. By harnessing naturally sourced excipients and reducing dependency on fossil-based polymers, the company aligns pharmaceutical innovation with environmental responsibility.
Let’s Collaborate
Whether you are developing a new drug or improving an existing product, Zerion Pharma offers scientifically proven, industrially feasible solutions for solubility enhancement. Reach out to explore formulation partnerships or technology access.
🔗 Visit Zerion Pharma here:
link: https://www.zerion.eu
Brochures
Contact
Zerion Pharma
Fruebjergvej 3
2100 Copenhagen
Denmark
Email: [email protected]
Website: Zerion Pharma website
LinkedIn: Zerion Pharma
